3,4-二氢-2H-1,5-苯并二氧-6-甲醛 | 209256-62-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3,4-二氢-2H-1,5-苯并二氧-6-甲醛
• 中文别名: 3,4-二氢-2H-1,5-苯并二噁英-6-甲醛
• 英文名称: 3,4-dihydro-2H-benzo[b][1,4]dioxane-6-carbaldehyde
• 英文别名: 3,4-dihydro-2H-benzo[b][1,4]dioxepine-6-carbaldehyde；2H-3,4-dihydro-1,5-benzodioxepin-6-carboxaldehyde；3,4-dihydro-2H-1,5-benzodioxepine-6-carbaldehyde
• CAS: 209256-62-2
• 化学式: C₁₀H₁₀O₃
• mdl: MFCD04972613
• 分子量: 178.188
• InChiKey: VXDUBVRFTGUJCJ-UHFFFAOYSA-N

物化性质

• 沸点：
  118 °C
• 密度：
  1.205±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2932999099

SDS

Name:	3 4-Dihydro-2h-1 5-benzodioxepine-6-carbaldehyde 97% Material Safety Data Sheet
Synonym:
CAS:	209256-62-2

Section 1 - Chemical Product MSDS Name:3 4-Dihydro-2h-1 5-benzodioxepine-6-carbaldehyde 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
209256-62-2	3,4-Dihydro-2H-1,5-benzodioxepine-6-ca	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 209256-62-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 74 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H10O3
Molecular Weight: 178.19

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 209256-62-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3,4-Dihydro-2H-1,5-benzodioxepine-6-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 209256-62-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 209256-62-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 209256-62-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3,4-二氢-2H-1,5-苯并二氧-6-甲醛 在 间氯过氧苯甲酸 、 potassium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 22.0h， 生成 3,4-dihydro-2H-benzo[b][1,4]dioxe-6-ol
  参考文献：
  名称：

  发现 2,3-二氢[1,4]二恶英[2,3-g]苯并呋喃衍生物作为蛋白酶激活受体 4 (PAR4) 拮抗剂，具有有效的抗血小板聚集活性和低出血倾向

  摘要：

  动脉栓塞性疾病患者从抗血小板治疗中获益匪浅。然而，抗血小板药物的出血风险也不容忽视。在此，我们描述了 2,3-二氢[1,4]二恶英[2,3- g ]苯并呋喃化合物作为新型 PAR4 拮抗剂的发现。值得注意的是，化学型为苯氧基亚甲基在 2,3-二氢-1,4-二恶英环上取代的异构体36和37表现出有效的体外抗血小板活性（ 36的 IC 50 = 26.13 nM， 37的 IC 50 = 14.26 nM），并且显着改善人肝微粒体的代谢稳定性（BMS-986120 36时T 1/2 = 97.6 分钟，11.1 分钟）。 36还表现出良好的口服 PK 特征（小鼠： T 1/2 = 7.32 h 和F = 45.11%）。两者在浓度为 6 和 12 mg/kg 时均表现出有效的体外抗血小板活性，对凝血系统没有影响且出血倾向低。我们的工作将促进新型 PAR4 拮抗剂的开发，作为动脉栓塞更安全的治疗选择。

  DOI：

  10.1021/acs.jmedchem.3c02099
• 作为产物：
  描述：

  邻香草醛 在 三溴化硼 、 caesium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3,4-二氢-2H-1,5-苯并二氧-6-甲醛
  参考文献：
  名称：

  胺类化合物的新用途

  摘要：

  本发明提供了胺类化合物的制备以及新用途。具体地，本发明提供了式A所示的化合物、或其光学异构体或其外消旋体、或其溶剂化物、或其药学上可接受的盐及其医药用途，它们被用于制备一药物组合物或制剂，所述药物组合物或制剂用于(a)抑制瞬时受体电位通道蛋白TRPA1；(b)治疗与瞬时受体电位通道蛋白相关的疾病，式中，各基团定义如说明书中所述。

  公开号：

  CN107840845A

文献信息

• 咪唑并环类PAR4拮抗剂及其医药用途
  申请人：中国药科大学

  公开号：CN110627817B

  公开（公告）日：2022-03-29

  本发明涉及式(I)或式(II)所示的咪唑并环类化合物、或其药学上可接受的盐或酯或溶剂化物。本发明的化合物可用于制备预防或治疗血栓栓塞性病症的药物。
• Regio- and Chemoselective Kumada–Tamao–Corriu Reaction of Aryl Alkyl Ethers Catalyzed by Chromium Under Mild Conditions
  作者：Xuefeng Cong、Huarong Tang、Xiaoming Zeng

  DOI：10.1021/jacs.5b08621

  日期：2015.11.18

  the cross-coupling reactions with aryl ethers via C-O bond activation have attracted broad interest. However, the functionalizations of C-O bonds are mainly limited to nickel catalysis, and selectivity has long been a prominent challenge when several C-O bonds are present in the one molecule. We report here the first chromium-catalyzed selective cross-coupling reactions of aryl ethers with Grignard reagents

  作为一种环境友好的合成工具，通过 CO 键活化与芳基醚的交叉偶联反应引起了广泛的兴趣。然而，CO 键的功能化主要限于镍催化，当一个分子中存在多个 CO 键时，选择性一直是一个突出的挑战。我们在这里报告了第一个铬催化的芳基醚与格氏试剂通过 CO（烷基）键断裂的选择性交叉偶联反应。在室温下使用简单、廉价的铬 (II) 预催化剂结合亚氨基助剂实现了多种转化。它为高效和选择性地构建官能化芳香醛提供了新途径。
• [EN] NOVEL CALCIUM SENSING RECEPTOR MODULATING COMPOUNDS AND PHARMACEUTICAL USE THEREOF<br/>[FR] NOUVEAUX COMPOSÉS MODULANT LE RÉCEPTEUR SENSIBLE AU CALCIUM, ET LEUR UTILISATION PHARMACEUTIQUE
  申请人：LEO PHARMA AS

  公开号：WO2010136037A1

  公开（公告）日：2010-12-02

  The invention relates to novel calcium-sensing receptor (CaSR) modulating substituted cyclopentylene compounds represented in formula I and derivatives thereof, to said compounds for use as a medicament, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

  该发明涉及一种表示为公式I的新型调节钙感受受体（CaSR）的取代环戊烯化合物及其衍生物，该化合物用作药物，用于治疗的化合物，包含该化合物的制药组合物，使用该化合物治疗疾病的方法以及使用该化合物制造药物。
• Compositions comprising multiple bioactive agents, and methods of using the same
  申请人：Berman M. Judd

  公开号：US20060142265A1

  公开（公告）日：2006-06-29

  In part, the present invention is directed to compositions comprising a FabI inhibitor and at least one other bioactive agent. In another part, the present invention is directed to antibacterial compositions comprising a compound of formulas I-III and at least one other antibacterial agent.

  本发明的一部分涉及含有FabI抑制剂和至少一种其他生物活性剂的组合物。另一部分，本发明涉及含有I-III式化合物和至少一种其他抗菌剂的抗菌组合物。
• Therapeutic agents, and methods of making and using the same
  申请人：Sargent Bruce J.

  公开号：US20100093705A1

  公开（公告）日：2010-04-15

  In part, the present invention is directed to antibacterial compounds.

  部分地，本发明是针对抗菌化合物的。